A Phase 1/2 interventional study of ASP2957 and Methylprednisolone in X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies. Recruiting at 5 sites in 2 countries. Open to male participants aged Up to 36 Months. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Myopathies, Structural, Congenital with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Myopathies, Structural, Congenital · United States.
Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, this one is one of 3 that started in 2025, is one of 2 in phase 1/2, and was the 11th registered.
24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.
Browse Myopathies, Structural, Congenital studies →4 of the 13 studies in Myopathies, Structural, Congenital with a site in United States are open now. Recruiting first, the newest first:
Astellas Gene Therapies · Sites in United States, Canada, United Kingdom
Ages up to 17 · Men only
Boston Children's Hospital · Sites in United States
University of Nevada, Las Vegas · Sites in United States
Ages 18–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Myopathies, Structural, Congenital studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: Up to 36 Months · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 23 across 10 interventional studies indexed under Myopathies, Structural, Congenital.
Median enrollment 27 across the 5 interventional studies, 41 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 8 most frequent:
This study is registered under Astellas Gene Therapies, one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Gene Therapies is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Astellas Pharma Inc has 6 studies filed under Myopathies, Structural, Congenital — fewer than ten, so there is no comparison to draw.
1 of the studies in Myopathies, Structural, Congenital with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07052929Astellas Gene TherapiesStudy of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM.
The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene cause low or no levels of myotubularin to be made, so the muscles do not work properly.
Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. Researchers have developed ASP2957 to get a healthy MTM1 gene into the body. This could help improve muscle development and function in young children with XLMTM.
In this study, ASP2957 will be given to humans for the first time.
ASP2957 has the healthy MTM1 gene inside a type of empty (killed) virus. The virus delivers the healthy MTM1 gene directly into cells in the body. It's possible that some boys may have antibodies to the virus if they have previously been infected with a similar virus. The antibodies could stop ASP2957 from working properly and cause an immune reaction to ASP2957. To prevent this, the boys will also be given medicines to lower the immune system.
The main aims of this study are to check the safety of ASP2957, how well it is tolerated, and to find a suitable dose of ASP2957.
The study was designed in 2 phases. In Phase 1, different small groups of boys will receive lower to higher doses of ASP2957. Each boy will receive a single infusion of ASP2957. Any medical problems will be recorded for each dose. This is done to find a suitable dose of ASP2957 to use in Phase 2.
In Phase 2, another small group of young boys will receive a single infusion of ASP2957. The most suitable dose of ASP2957 worked out from Phase 1 will be used.
The boys will be checked for up to 1 year after their single infusion of ASP2957. After this, there will be the option for the boys to join another study so they will continue to be checked longer term.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant is ventilator-dependent and meets the following criteria:
Participant's parent(s) or legally authorized representative LAR(s) must provide documentation of being current with recommended immunization schedule according to regional guidelines.
Exclusion Criteria:
Participant requires supplemental oxygen on a routine or chronic basis.
Participant has an active viral or bacterial infection including, but not limited to, positive testing for the following:
Participant has any history of cholestatic liver dysfunction and/or treatment for cholestasis. If the participant is taking prophylactic treatment for cholestasis (e.g., ursodiol, cholestyramine, rifampin or other therapies) which has not been prescribed for cholestatic liver dysfunction, treatment must be discontinued for at least 4 weeks prior to signing the ICF.
Participant has musculoskeletal complications such as severe contractures and/or scoliosis that would limit the ability to observe improvements in neuromuscular function.
Participant has previously received monoclonal antibodies of any type.
Participant plans to have surgery within 12 weeks prior to day 1 through week 52 that may confound safety and efficacy data interpretation of the study intervention.
Participant tests positive for anti-MyoAAV3.8 TAb, as determined by central laboratory testing.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive sequential dose levels of a single infusion of ASP2957 and immunosuppression prophylaxis including methylprednisolone, prednisolone and sirolimus.
Genetic: ASP2957 · Drug: Methylprednisolone · Drug: Prednisolone · Drug: Sirolimus
Participants will receive a single infusion of ASP2957 (dose selected in Part 1) and immunosuppression prophylaxis including methylprednisolone, prednisolone and sirolimus.
Genetic: ASP2957 · Drug: Methylprednisolone · Drug: Prednisolone · Drug: Sirolimus
Intravenous infusion
Also known as: MyoAAV3.8 engineered capsid - myosin heavy chain kinase 7 - human myotubularin (MyoAAV3.8-MHCK7-hMTM1)
Intravenous infusion
Route of administration based on locally sourced product
Route of administration based on locally sourced product
Number of participants with treatment emergent adverse events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures. A TEAE is defined as an AE observed after administration of ASP2957.
Time frame: Up to week 52
Number of participants with adverse events of special interest (AESIs)
AESIs include myocardial-associated events, muscle abnormalities, hepatobiliary disorders, thrombocytopenia, TMA and life-threatening infections.
Time frame: Up to week 52
Number of participants with laboratory value abnormalities and/or adverse events (AEs)
Number of participants with potentially clinically significant laboratory values.
Time frame: Up to 52 weeks
Number of participants with electrocardiogram (ECG) abnormalities and/or AEs
Number of participants with potentially clinically significant ECGs.
Time frame: Up to 52 weeks
Number of participants with echocardiogram (ECHO) abnormalities and/or AEs
Number of participants with potentially clinically significant ECHOs.
Time frame: Up to 52 weeks
Number of participants with muscle magnetic resonance imaging (MRI) abnormalities and/or AEs
Number of participants with potentially clinically significant muscle MRIs.
Time frame: Up to 52 weeks
Number of participants with histopathology abnormalities and/or AEs from muscle biopsy
Number of participants with potentially clinically significant histopathology from muscle biopsy.
Time frame: Up to 52 weeks
Number of participants with physical examinations abnormalities and/or AEs
Number of participants with potentially clinically significant physical examinations.
Time frame: Up to 52 weeks
Change from baseline in hours per day of ventilation support at week 52
The hours of ventilation support will be collected.
Time frame: Baseline and up to week 52
ASP2957 vector deoxyribonucleic acid (DNA) in serum through week 52
ASP2957 vector DNA will be recorded from serum samples collected.
Time frame: Up to week 52
ASP2957 vector DNA in muscle biopsy at week 52
ASP2957 vector DNA will be recorded from muscle biopsy collected.
Time frame: Week 52
ASP2957 vector DNA in saliva
ASP2957 vector DNA will be recorded from saliva samples collected.
Time frame: Up to week 52
ASP2957 vector DNA in urine
ASP2957 vector DNA will be recorded from urine samples collected.
Time frame: Up to week 52
ASP2957 vector DNA in stool
ASP2957 vector DNA will be recorded from stool samples collected.
Time frame: Up to week 52
Anti-MyoAAV3.8 total antibody (TAb)
Anti-MyoAAV3.8 TAb will be recorded from serum samples collected
Time frame: Up to week 52
Anti-MyoAAV3.8 neutralizing antibody (NAb)
Anti-MyoAAV3.8 NAb will be recorded from serum samples collected.
Time frame: Up to week 52
Anti-myotubularin TAb
Anti-myotubularin TAb will be recorded from serum samples collected.
Time frame: Up to week 52
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methylprednisolone · Prednisolone · Sirolimus
Myopathies, Structural, Congenital →